MiMedx Outlines Revenue Target Exceeding $400M by 2027 with Over 20% Adjusted EBITDA Margin Following Sanara Acquisition
MiMedx Group, Inc. (NASDAQ: MDXG) has outlined a financial outlook projecting revenue well above $400 million in fiscal year 2027 and an adjusted EBITDA margin of over 20%. These projections follow the company's announcement that it reached a definitive agreement to acquire all outstanding shares of Sanara MedTech. The acquisition is expected to enhance MiMedx’s market position within its sector, leveraging synergies from combining operations with Sanara. The Q2 2026 earnings call provided insights into how management anticipates the deal will contribute significantly to future revenue and profitability metrics. By integrating Sanara's product portfolio and customer base, MiMedx aims to strengthen its competitive edge in medical technologies while improving operational efficiencies.
